<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701675</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-005-04F</org_study_id>
    <nct_id>NCT00701675</nct_id>
  </id_info>
  <brief_title>Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly</brief_title>
  <acronym>Sert-GAD</acronym>
  <official_title>Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Generalized anxiety disorder (GAD) is a very common disorder in the geriatric population with
      prevalence rates reaching 7% and even higher rates of 8% among elderly veterans. However,
      despite such high prevalence treating clinicians are presently forced to address treatment
      issues in this population without the guidance of scientific data. This proposal aims to
      begin to address this void.

      In light of emerging information regarding efficacy of the newer anti anxiety agents,
      specifically the selective serotonin reuptake inhibitors (SSRIs), in the treatment of young
      adult GAD patients it is time to prospectively evaluate the safety and efficacy of these
      medications in the treatment of elderly GAD patients. Therefore, this study will examine the
      effects and safety of the SSRI sertraline at different doses (50mg and 100mg per day) for
      older patients with GAD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Generalized anxiety disorder (GAD) is a serious and distinct illness that occurs in
      significant numbers, affecting at least 7 million people in the United States alone. The
      prevalence of GAD is higher in the primary care setting with rates twice as high as the rates
      reported in community samples. GAD is a life-long disorder with low remission rates,
      resulting in high disability and morbidity. Of significance are emerging epidemiological data
      suggesting that GAD is highly prevalent in the geriatric population with prevalence rates
      ranging from 1.9% to 7.1% and accounting for the majority of anxiety disorder cases in this
      age group. More alarming is the fact that the presence of anxiety symptoms leads to
      considerable functional impairment, increased morbidity, and mortality among the affected
      elderly population, thus leading to increases in the costs of their care. However, despite
      advances made in GAD treatment in the adult population, no prospective data are presently
      available on the treatment of GAD in the elderly population, forcing clinicians to provide
      treatment without the guidance of scientific data. These findings are of particular relevance
      to the Veterans Affairs Health Care System where the average age of patients treated in
      primary care clinics is currently 60-64 years. The present application focuses on this target
      subpopulation of elderly veterans.

      This proposal aims to provide evidence-based guidelines for pharmacological management of
      elderly veterans suffering from generalized anxiety disorder. This will be accomplished by
      conducting a clinical trial in elderly veterans suffering from GAD by evaluating the efficacy
      and safety of sertraline - a proven anxiolytic compound widely used in the young adult
      population.

      We believe that this proposed study will be one of the first studies in this area. Thus, it
      may also serve as a first step in a future line of research aimed at developing comprehensive
      pharmacological and psychosocial interventions in the treatment of anxiety in the elderly.

      (b) HYPOTHESIS/RESEARCH QUESTIONS Study Hypothesis In a double-blind, placebo-controlled
      trial in elderly veterans diagnosed with GAD, sertraline will be more effective and equally
      safe as placebo in reducing symptoms of generalized anxiety disorder.

      Research Question Will the presence of differences in pharmacokinetics (PK) (i.e., mean
      population values of steady state plasma concentrations) and plasma levels of sertraline
      explain differences in efficacy and side effect profile between and within the two fixed
      sertraline doses studied, if detected? (c) SPECIFIC OBJECTIVE The objective of the proposed
      study is to conduct a multi-site, double-blind, placebo-controlled trial evaluating the
      efficacy and safety of sertraline at fixed doses vs. placebo in the treatment of GAD among
      elderly primary care outpatient veterans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg</measure>
    <time_frame>11 weeks from baseline</time_frame>
    <description>Least squares (LS) means estimate and p-value from mixed effects model with baseline and site as covariates and Tukey-Kramer adjustment for multiple comparisons Hamilton Rating Scale for Anxiety (HAM-A) is a widely used rating scale for anxiety describes the presence/absence of the severity of anxiety symptoms. It's clinician-rated scale of 14 items rated from 0-4. Generally, total score of &lt;17 is mild anxiety; 18-24 is mild to moderate, and 25 and up is moderate to severe.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>Sertraline 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sertraline 50 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertraline 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sertraline 100mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 50 or 100mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline 50 mg daily</intervention_name>
    <description>50 mg daily</description>
    <arm_group_label>Sertraline 50mg</arm_group_label>
    <other_name>zoloft 50 mg daily</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline 100 mg daily</intervention_name>
    <description>100 mg daily</description>
    <arm_group_label>Sertraline 100mg</arm_group_label>
    <other_name>zoloft 100mg daily</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 50 or 100 mg</intervention_name>
    <description>50mg or 100mg matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>50mg or 100mg matching placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females of any race, ages 60 years and older.

          -  Willingness to accept randomization.

          -  Subjects who meet current (Diagnostic and Statistical Manual of Psychiatric Disorders
             forth edition (DSM-IV) criteria for a principal diagnosis of GAD

          -  Patients must have a minimum of a &quot;moderately ill&quot; rating on the Clinicians Global
             Impression-Severity Scale for GAD.

          -  Patients will have a score of 10 or more on the Hospital Anxiety and Depression Rating
             Scale (HADS) Anxiety subscale.

          -  Subjects entering the study will be free of psychotropic medications.

        Exclusion Criteria:

          -  Subjects with DSM-IV current major depressive episode will be excluded.

          -  Subjects who exhibit suicidal ideation or are judged to be a significant suicide risk.

          -  Subjects who meet DSM-IV criteria for a substance (drug and alcohol) abuse and
             dependence disorder within the past 6 months

          -  Subjects who meet current or past DSM-IV criteria for psychotic disorder, or bipolar
             disorder.

          -  Subjects who meet DSM-IV criteria for dementia.

          -  Subjects with DSM-IV current major depressive episode will be excluded.

          -  Subjects who exhibit suicidal ideation or are judged to be a significant suicide risk.

          -  Subjects who meet DSM-IV criteria for a substance (drug and alcohol) abuse and
             dependence disorder within the past 6 months

          -  Subjects who meet current or past DSM-IV criteria for psychotic disorder, or bipolar
             disorder.

          -  Subjects who meet DSM-IV criteria for dementia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Brawman-Mintzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ralph H Johnson VA Medical Center, Charleston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Tuscaloosa</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System, Miami, FL</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralph H Johnson VA Medical Center, Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401-5799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <results_first_submitted>January 16, 2014</results_first_submitted>
  <results_first_submitted_qc>November 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 29, 2016</results_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sertraline</keyword>
  <keyword>pharmacotherapy</keyword>
  <keyword>geriatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sertraline 50mg</title>
          <description>sertraline 50mg per day
sertraline 50 mg daily: 50 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Sertraline 100mg</title>
          <description>sertraline 100mg per day
sertraline 100 mg daily: 100 mg daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>matching placebo
Placebo 50 or 100 mg: matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sertraline 50mg</title>
          <description>sertraline 50mg per day
sertraline 50 mg daily: 50 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Sertraline 100mg</title>
          <description>sertraline 100mg per day
sertraline 100 mg daily: 100 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>matching placebo
Placebo 50 or 100 mg: matching placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg</title>
        <description>Least squares (LS) means estimate and p-value from mixed effects model with baseline and site as covariates and Tukey-Kramer adjustment for multiple comparisons Hamilton Rating Scale for Anxiety (HAM-A) is a widely used rating scale for anxiety describes the presence/absence of the severity of anxiety symptoms. It's clinician-rated scale of 14 items rated from 0-4. Generally, total score of &lt;17 is mild anxiety; 18-24 is mild to moderate, and 25 and up is moderate to severe.</description>
        <time_frame>11 weeks from baseline</time_frame>
        <population>sertraline 50mg group and placebo group each had 2 subjects with missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline 50mg</title>
            <description>sertraline 50mg per day
sertraline 50 mg daily: 50 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Sertraline 100mg</title>
            <description>sertraline 100mg per day
sertraline 100 mg daily: 100 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>matching placebo
Placebo 50 or 100 mg: matching placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg</title>
          <description>Least squares (LS) means estimate and p-value from mixed effects model with baseline and site as covariates and Tukey-Kramer adjustment for multiple comparisons Hamilton Rating Scale for Anxiety (HAM-A) is a widely used rating scale for anxiety describes the presence/absence of the severity of anxiety symptoms. It's clinician-rated scale of 14 items rated from 0-4. Generally, total score of &lt;17 is mild anxiety; 18-24 is mild to moderate, and 25 and up is moderate to severe.</description>
          <population>sertraline 50mg group and placebo group each had 2 subjects with missing data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.638" lower_limit="7.456" upper_limit="13.819"/>
                    <measurement group_id="O2" value="10.008" lower_limit="5.692" upper_limit="14.323"/>
                    <measurement group_id="O3" value="9.357" lower_limit="5.159" upper_limit="13.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>weeks 1,2,3,5,7,9,and 11</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sertraline 50mg</title>
          <description>sertraline 50mg per day
sertraline 50 mg daily: 50 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Sertraline 100mg</title>
          <description>sertraline 100mg per day
sertraline 100 mg daily: 100 mg daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>matching placebo
Placebo 50 or 100 mg: matching placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>jitteriness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>oral surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Olga Brawman-Mintzer, MD</name_or_title>
      <organization>Ralp H. Johnson VA Medical Center</organization>
      <phone>8437242302 ext 2834</phone>
      <email>mintzero@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

